四环生物(000518) - 2021 Q2 - 季度财报

Financial Performance - The company's operating revenue for the reporting period was ¥149,748,660.35, a decrease of 36.70% compared to ¥236,569,960.74 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was -¥27,669,307.65, representing a decline of 539.43% from ¥6,296,576.38 in the previous year[20]. - The net cash flow from operating activities was -¥12,832,855.88, down 119.86% from ¥64,607,780.69 in the same period last year[20]. - The basic earnings per share were -¥0.0269, a decrease of 540.98% compared to ¥0.0061 in the previous year[20]. - The company reported a net loss of CNY 490,708,726.40 in retained earnings, worsening from a loss of CNY 463,039,418.75 at the end of 2020[107]. - The net loss for the first half of 2021 was CNY 31.57 million, compared to a net profit of CNY 4.52 million in the same period of 2020[115]. - The total comprehensive income for the period was 11,325.59 million yuan, showcasing the company's robust performance despite market challenges[134]. Assets and Liabilities - Total assets at the end of the reporting period were ¥817,762,509.17, a decrease of 0.72% from ¥823,707,532.72 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company were ¥613,154,224.68, down 4.32% from ¥640,823,532.33 at the end of the previous year[20]. - Total liabilities increased to CNY 164,285,125.32 from CNY 138,659,527.09, marking an increase of approximately 18.4%[106]. - The total liabilities of the company were not detailed in the provided documents, indicating a focus on equity rather than debt management[130]. Revenue Segmentation - The pharmaceutical segment generated ¥127,784,414.56, accounting for 85.33% of total revenue, with a year-on-year increase of 32.49%[35]. - The landscape engineering segment's revenue was ¥7,655,267.02, showing a growth of 4.01% compared to the previous year[35]. - Total operating revenue for the first half of 2021 was CNY 149.75 million, a decrease of 36.67% compared to CNY 236.57 million in the same period of 2020[112]. Research and Development - Research and development expenses increased by 201.15% to ¥41,376,753.42, reflecting the addition of new R&D projects[33]. - The company holds 5 invention patents and 3 new drug certificates, indicating a strong position in biopharmaceutical R&D[31]. - The company is focusing on research and development of new technologies to drive future growth and innovation in its product offerings[134]. Cash Flow and Financing - Cash and cash equivalents decreased to ¥39,469,926.67, representing 4.83% of total assets, down from 6.63% last year, a decrease of 1.80%[39]. - The company incurred a net cash outflow from investing activities of CNY -1,957,318.77, compared to a net outflow of CNY -1,680,805.63 in the previous year[124]. - The company received CNY 16,000,000.00 from borrowings, which was consistent with the previous year, indicating stable financing activities[124]. Shareholder Information - The company reported a total of 1,029,556,222 shares outstanding, with 100% being unrestricted shares[89]. - The total number of ordinary shareholders at the end of the reporting period was 127,376[91]. - The largest shareholder, Wang Hongming, holds 14.00% of the shares, amounting to 144,138,394 shares, with a pledge on 144,130,000 shares[91]. Corporate Governance and Compliance - The company has not engaged in any significant related party transactions during the reporting period[72]. - The company and its subsidiaries are not classified as key pollutant discharge units and have not faced any environmental penalties[59]. - There were no major contracts or leasing matters reported during the period[78]. Market and Industry Context - The pharmaceutical industry is characterized by strong demand and is less affected by macroeconomic fluctuations, with increasing importance in the national economy[28]. - The company faces risks related to industry policies, R&D, accounts receivable management, and inventory management, which may impact operations and financial performance[49][50]. Accounting and Financial Reporting - The financial statements are prepared based on the going concern assumption and comply with the relevant accounting standards[141]. - The company recognizes expected credit losses for financial assets, with provisions based on the expected credit loss over the entire life of the asset[169]. - The company uses Renminbi as its functional currency for accounting purposes[147].